Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2011-05-23 · Food and Drug Administration, HHS · Notices

Notices. Notice; reopening of the comment period

506 words·~2 min read·/register/2011/05/23/2011-12617

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2010-N-0633] Determination of System Attributes for the Tracking and Tracing of Prescription Drugs; Reopening of the Comment Period AGENCY: Food and Drug Administration, HHS. ACTION: Notice; reopening of the comment period. SUMMARY: The Food and Drug Administration
(FDA)is reopening the comment period for the notice of public workshop published in the **Federal Register** of January 7, 2011 (76 FR 1182). In that notice, FDA announced a public workshop that took place on February 15 and 16, 2011, and requested public comment regarding the topics discussed at the workshop on determining system attributes for tracking and tracing prescription drugs. The workshop provided a forum for discussing possible approaches to developing a track-and-trace system and for obtaining input from supply chain partners on potential attributes and standards for the identification, authentication, and tracking and tracing of prescription drug packages. FDA is reopening the comment period to allow additional time for interested persons both to consider all the information provided by the Agency related to the workshop and to submit additional comments. DATES: Submit either electronic or written comments by June 22, 2011. ADDRESSES: Submit electronic comments to *http://www.regulations.gov.* Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Connie Jung, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-3100, *connie.jung@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: I. Background In the **Federal Register** of January 7, 2011 (76 FR 1182), FDA published a notice announcing a public workshop entitled “Determination of System Attributes for the Tracking and Tracing of Prescription Drugs; Public Workshop.” In that notice, FDA requested the following:
(1)Input and comments from interested stakeholders regarding possible approaches to developing a track-and-trace system and
(2)input from supply chain partners on potential attributes and standards for the identification, authentication, and tracking and tracing of prescription drug packages. Interested persons were originally given until April 16, 2011, to submit comments. II. Request for Comments On April 4, 2011, FDA posted on the FDA Web site a summary of the main comments shared by the public workshop participants. To allow adequate time for interested persons both to consider all the information provided by the Agency related to the workshop and to submit additional comments, FDA is reopening the comment period. III. How to Submit Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES ) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: May 13, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011-12617 Filed 5-20-11; 8:45 am]
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.